Pioneers in cancer care

The Aktis Oncology team is pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumors.

Aktis Leadership Team

Matthew Roden, PhD

Matthew Roden, PhD

Matthew Roden, PhD

President, Chief Executive Officer

Paul L. Feldman, PhD

Paul L. Feldman, PhD

Paul L. Feldman, PhD

Chief Scientific Officer

Pankaj Bhargava, MD

Pankaj Bhargava, MD

Pankaj Bhargava, MD

INTERIM CHIEF
MEDICAL OFFICER

Brian Goodman, PhD

Brian Goodman, PhD

Brian Goodman, PhD

Co-founder, Chief Operating Officer

Ved Srivastava, PhD

Ved Srivastava, PhD

Ved Srivastava, PhD

Vice President, Head of Chemistry

Karen McCarthy

Karen McCarthy

Karen McCarthy

Executive Director,
Head of Finance

Jeff Kovacs, PhD

Jeff Kovacs, PhD

Jeff Kovacs, PhD

Executive Director, Head of Oncology

Tyler Benedum, PhD

Tyler Benedum, PhD

Tyler Benedum, PhD

Senior Vice President, Head of Chemistry, Manufacturing, and Controls

Daša Lipovšek, PhD

Daša Lipovšek, PhD

Daša Lipovšek, PhD

Vice President, Head of Lead Discovery

Aktis Board of Directors

Todd Foley

Co-founder and Chairman

Helen Kim, MBA

Director

Oleg Nodelman

Director

Matthew Roden, PhD

Director

Lloyd M. Segal, MBA

INDEPENDENT DIRECTOR

Jim Carmichael, MD

OBSERVER

View Bio

Maurizio Mariani, MD, PhD

OBSERVER

View Bio

Alex Tkachenko, PhD

OBSERVER

View Bio

Aktis Scientific Advisors

Ken Herrmann, MD

Chair, Scientific Advisory Board

Patrick Beauerle, PhD

Co-founder & Advisor

Erik Chelius, PhD

Advisor

Johannes Czernin, MD

Advisor

Gary Glick, PhD

Advisor

Dane Wittrup, PhD

Advisor

Investors

Join us

Join a team dedicated to discovering and developing transformative therapies that put solid cancers into remission.

View Careers

Scientist in lab coat working at computer desk